Neubase Therapeutics Inc (NBSE) Return on Equity ROE from the third quarter 2023 to third quarter 2022 and annually, average high and low, overall ranking from Sep 30 2023 to Sep 30 2022 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Neubase Therapeutics inc   (NASDAQ: NBSE)

Neubase Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Neubase Therapeutics Inc in the third quarter 2023?
Neubase Therapeutics Inc recorded a cumulative net loss of $-14 million during 12 months ending in the third quarter 2023, resulting in a negative return on equity (ROE) of -103.52%.

Within the Major Pharmaceutical Preparations industry 297 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 3583, from total ROE ranking in the second quarter 2023 at 3802.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
I. Quarter		 (Sep 30 2022)
IV. Quarter
Y / Y Equity Change -60.6 % -62.9 % -62.14 % -61.34 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -14 -22 -27 -32 -36
Return On Equity (TTM) -103.52 % -128.61 % -123.57 % -118.13 % -103.21 %
NBSE's Total Ranking # 3583 # 3802 # 0 # 3830 # 0
Equity (TTM) in Millions 9 11 14 18 23
Seq. Equity Change -18.76 % -22.16 % -20.72 % -21.42 % -23.49 %
Seq. Net Income Change - - - - -

Back to NBSE Management Effectiveness >> NBSE's 5 Years Annual ROE >> Compare NBSE ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 298
Sector # 648
Overall # 3583

Return On Equity Statistics
High Average Low
-38.25 %
-108.85 %
-466.42 %
(Dec 31 2015)   (Mar 31 2020)





NBSE Annual Return On Equity (Sep 30 2022)
2022		 (Sep 30 2021)
2021		 (Sep 30 2020)
2020		 (Sep 30 2019)
2019		 (Sep 30 2018)
2018
Total Equity in Millions 23 54 31 10 11
Y / Y Equity Change -57.11 % 72.78 % 212.03 % -8 % -52.28 %
Net Income in Millions -34 -25 -17 -27 -13
Y / Y Net Income Change - - - - -
Return On Equity -145.64 % -46.99 % -55.55 % -268.79 % -121.43 %

Back to NBSE Management Effectiveness >> NBSE's 5 Years Annual ROE >> Compare NBSE ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NBSE's' Return on Equity at Yahoo Finance
NBSE's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NBSE's Competitors
Subscribers only: Roe for Neubase Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for NBSE's Customers




Companies with similar Return On Equity at Sep 30 2023, within Healthcare Sector ROE

Date modified: 2026-09-08T15:22:12+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.